The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis.

导出 OA

翻译打印收藏纠错

第一作者： Shaymaa,Glhoom

第一单位： Faculty of Pharmacy, Tanta University, Tanta, Egypt. phshimaamagdy@gmail.com.

作者： Shaymaa,Glhoom ^[1] ; Aya,Fergany ^[2] ; Dina,El-Araby ^[3] ; Asmaa A,Abdelkhalek ^[4] ; Asmaa,Gomaa ^[5] ; Eman O,Zayed ^[6] ; Mohamed,Abd-ElGwad ^[7]

作者单位： Faculty of Pharmacy, Tanta University, Tanta, Egypt. phshimaamagdy@gmail.com. ^[1] Microbiology and Immunology Department, Faculty of Pharmacy, New Valley University, EL-Kharja, Egypt. ^[2] Medical Agency for Research and Statistics, Giza, Egypt. ^[3] Faculty of Pharmacy, MSA University, Giza, Egypt. ^[4] Zoology Department, Faculty of Science, Al Azhar University, Cairo, Egypt. ^[5] Faculty of Pharmacy, Cairo University, Cairo, Egypt. ^[6] Faculty of Medicine, Fayoum University, Fayoum, Egypt. ^[7]

关键词 AZD7442 COVID-19 Cilgavimab Evusheld Tixagevimab

主题词人类(Humans);抗体, 单克隆(Antibodies, Monoclonal);免疫减弱宿主(Immunocompromised Host);复方合剂(Drug Combinations);抗体, 中和(Antibodies, Neutralizing)

DOI 10.1186/s40001-023-01549-x

PMID 38183123

发布时间 2024-03-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交